Research of Targeted Therapy for Renal Cancer from 2006 to 2022: a Bibliometric and Visualized Analysis

Overview

Journal Transl Androl Urol

Date 2023 Apr 10

PMID 37032755

Authors

Yuanqing Gou

Yongxin Fu

Yadong Li

Chuan Liu

Affiliations

Soon will be listed here.

Abstract

Background: This review aimed to analyze the research progress and development trends in targeted therapy (TT) for renal cancer (RC) from 2006 to 2022.

Methods: The Web of Science Core Collection database was searched using the search terms "renal cancer", "kidney neoplasms", "kidney cancer", and "targeted therapy", and all publications were extracted. VOSviewer version 1.6.18 was used to complete the visual analysis based on the information of publications, including author, journal, subject, year, and institution.

Results: A total of 1,136 studies related to TT for RC were found. The top journals in this field were the , , and . Among them, the had the highest number of publications (n=35). In terms of country, the United States had the highest number of publications (n=366). The main document type was article, which accounted for 64.26% of the total publications.

Conclusions: To the best of our knowledge, this is the first bibliometric analysis related to TT for RC. The annual number of publications has exhibited a steady growth trend, with the United States having the greatest contribution in this field. Through an analysis of a keyword time density map, we identified that hypoxia-inducing factor-1, drug resistance and therapeutic targets are the research hotspots and trends in this field.

Citing Articles

A 23-year bibliometric analysis of the development of global research on hereditary renal carcinoma.

Lan X, Feng M, Lv J, Zhang L, Hu P, Wang Y Front Oncol. 2024; 14:1364997.

PMID: 38887238 PMC: 11180816. DOI: 10.3389/fonc.2024.1364997.

Global research trends and mapping knowledge structure of depression in dialysis patients.

Al-Jabi S World J Psychiatry. 2023; 13(8):593-606.

PMID: 37701544 PMC: 10494777. DOI: 10.5498/wjp.v13.i8.593.

References

Muto A, Gridelli C . New immunotherapy in the treatment of advanced renal cancer. Expert Opin Emerg Drugs. 2019; 24(4):233-237. DOI: 10.1080/14728214.2019.1696308. View

Su C, Lv Y, Lu W, Yu Z, Ye Y, Guo B . Single-Cell RNA Sequencing in Multiple Pathologic Types of Renal Cell Carcinoma Revealed Novel Potential Tumor-Specific Markers. Front Oncol. 2021; 11:719564. PMC: 8551404. DOI: 10.3389/fonc.2021.719564. View

Amato R, Jac J, Giessinger S, Saxena S, Willis J . A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer. 2009; 115(11):2438-46. DOI: 10.1002/cncr.24280. View

Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt T . Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int. 2011; 108(10):1556-63. DOI: 10.1111/j.1464-410X.2011.10629.x. View

Chen C, Song M . Visualizing a field of research: A methodology of systematic scientometric reviews. PLoS One. 2019; 14(10):e0223994. PMC: 6822756. DOI: 10.1371/journal.pone.0223994. View

Qu L, Ding J, Chen C, Wu Z, Liu B, Gao Y . Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA. Cancer Cell. 2016; 29(5):653-668. DOI: 10.1016/j.ccell.2016.03.004. View

Rixe O, Bukowski R, Michaelson M, Wilding G, Hudes G, Bolte O . Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol. 2007; 8(11):975-84. DOI: 10.1016/S1470-2045(07)70285-1. View

Roldan-Valadez E, Salazar-Ruiz S, Ibarra-Contreras R, Rios C . Current concepts on bibliometrics: a brief review about impact factor, Eigenfactor score, CiteScore, SCImago Journal Rank, Source-Normalised Impact per Paper, H-index, and alternative metrics. Ir J Med Sci. 2018; 188(3):939-951. DOI: 10.1007/s11845-018-1936-5. View

Cowman S, Fuja D, Liu X, Slack Tidwell R, Kandula N, Sirohi D . Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer. Clin Cancer Res. 2020; 26(18):4970-4982. PMC: 7968518. DOI: 10.1158/1078-0432.CCR-19-3890. View

10.

Goh V, Ganeshan B, Nathan P, Juttla J, Vinayan A, Miles K . Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker. Radiology. 2011; 261(1):165-71. DOI: 10.1148/radiol.11110264. View

11.

Abushamma F, Barqawi A, Al-Jabi S, Akkawi M, Maree M, Zyoud S . Global Analysis of Research Trends on Kidney Function After Nephron-Sparing Surgery: A Bibliometric and Visualised Study. Cancer Manag Res. 2021; 13:7479-7487. PMC: 8485850. DOI: 10.2147/CMAR.S324284. View

12.

Albiges L, Tannir N, Burotto M, McDermott D, Plimack E, Barthelemy P . Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open. 2020; 5(6):e001079. PMC: 7703447. DOI: 10.1136/esmoopen-2020-001079. View

13.

Xu Z, Liu M, Wang J, Liu K, Xu L, Fan D . Single-cell RNA-sequencing analysis reveals MYH9 promotes renal cell carcinoma development and sunitinib resistance via AKT signaling pathway. Cell Death Discov. 2022; 8(1):125. PMC: 8941107. DOI: 10.1038/s41420-022-00933-6. View

14.

Linehan W, Srinivasan R, Schmidt L . The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol. 2010; 7(5):277-85. PMC: 2929006. DOI: 10.1038/nrurol.2010.47. View

15.

Rafiyan M, Jager E . [Drug treatment of metastatic renal cell carcinoma]. Dtsch Med Wochenschr. 2013; 138(31-32):1567-70. DOI: 10.1055/s-0033-1343291. View

16.

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. JAMA Oncol. 2019; 5(10):1411-1420. PMC: 6659167. DOI: 10.1001/jamaoncol.2019.2187. View

17.

Catto J, Alcaraz A, Bjartell A, de Vere White R, Evans C, Fussel S . MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol. 2011; 59(5):671-81. DOI: 10.1016/j.eururo.2011.01.044. View

18.

Drake C, Lipson E, Brahmer J . Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol. 2013; 11(1):24-37. PMC: 4086654. DOI: 10.1038/nrclinonc.2013.208. View

19.

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

20.

Yip S, Ruiz Morales J, Donskov F, Fraccon A, Basso U, Rini B . Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC). Kidney Cancer. 2018; 1(1):41-47. PMC: 6179119. DOI: 10.3233/KCA-160002. View